BIIB115-Matching Placebo

Phase 1

BIIB115-Matching Placebo is one of 4 therapeutic programs targeting Muscular Atrophy, Spinal. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Muscular Atrophy, SpinalActive, not recruiting

Muscular Atrophy, SpinalPhase 1

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Muscular Atrophy, Spinal

#DrugCompanyPhaseTrials

Evrysdi

Roche

Approved

4 2

Salanersen

Biogen

Phase 3

1 3

BIIB115

Biogen

Phase 1

1 4

BIIB115-Matching Placebo

Biogen

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 1Active, not recruiting

Muscular Atrophy, Spinal

NCT05575011

Clinical

Trials by Indication[1]

Muscular Atrophy, Spinal1 trial

A Randomized, Blinded, Placebo-Controlled, Phase 1 Single Ascending Dose Study in Healthy Adult Male Volunteers and an Open-Label Multiple Ascending Dose Study With Long-Term Extension in Pediatric SMA Participants Previously Treated With Onasemnogene Abeparvovec (Zolgensma™) to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115

Active, not recruiting· Biogen logo

Biogen·Phase 1·NCT05575011·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BIIB115-Matching Placebo. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for BIIB115-Matching Placebo. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Biogen

BIIB115-Matching Placebo

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Muscular Atrophy, Spinal1 trial

References

Drug Info

Quick Facts

Related News